Bli medlem
Bli medlem

Du är här


Oxford Immunotec: Oxford Immunotec Recognizes World TB Day Through Support of the Winner of the Sir John Crofton Award

OXFORD, United Kingdom and MARLBOROUGH, Mass., March 24, 2015 (GLOBE NEWSWIRE)
-- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage
diagnostics company focused on developing and commercializing proprietary
tests for the management of immune-regulated conditions, today announced its
support of the recipient of the 2015 Sir John Crofton Prize for TB Nursing.

The Sir John Crofton Prize for TB Nursing has been established by TB Alert and
TB Action Group to identify and acknowledge exceptional TB nursing. The prize
celebrates outstanding individuals or teams who have demonstrated innovation
and excellence during the last two years through their advocacy and service
initiatives. The recipient of the prize has shown exemplary care, dedication
and leadership in clinical care, social support and public health. The prize
is named after Sir John Crofton who was a pioneer in the treatment of
tuberculosis, served as a chair for the International Union Against
Tuberculosis and Lung Disease (IUATLD), and co-authored the World Health
Organization's guidelines for the treatment of tuberculosis.

The Homerton Hospital TB nurses in the London Borough of Hackney were selected
as the winner of this year's prize for housing homeless TB patients with no
recourse to public funds. The Homerton Hospital TB nurses often encounter TB
among homeless migrants, who do not qualify for welfare support. The care of
this population is complex and treatment is often difficult. The Homerton
Hospital TB Nurses found that by housing this population for the duration of
their treatment, completion rates increased by 1.6% to 91.4%, in just one

The Homerton Hospital TB team demonstrated the very best of TB nursing -
showing compassion and using innovative ideas to tackle TB. "Oxford Immunotec
is proud to stand alongside TB nurses with the goal of eliminating TB as a
public health concern worldwide," says Dr. Peter Wrighton-Smith, Chief
Executive Officer at Oxford Immunotec. Oxford Immunotec is a proud sponsor of
the award this year and is providing funds for the winner to use towards
continuing professional development.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company
focused on developing and commercializing proprietary tests for the
management of immune-regulated conditions. The Company's initial product is
the T-SPOT®.TB
test, which is used to test for tuberculosis infection. The T-SPOT.TB
test has been approved for sale in over 50 countries, including the United
States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The Company has seven active development programs, each of which
leverages our T cell and innate immune measuring technology. The two most
advanced products are focused on the transplantation market. The Company is
headquartered near Oxford, UK and in Marlborough, MA. Additional information
can be found

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

About TB Alert

( is the UK's national tuberculosis charity, and is the only
charity that focuses on TB both in the UK and overseas, and works nationally
and locally to raise awareness about TB in the UK.

About TB Action Group

The TB Action Group (TBAG) is a network for people affected by TB in the UK.
TBAG members provide support to TB patients and use their stories and
insights to advocate for better TB services


For Media Inquiries:

Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.